| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9149(98)00586-4 |
| P698 | PubMed publication ID | 9809901 |
| P2093 | author name string | W G Stevenson | |
| P L Friedman | |||
| P2860 | cites work | Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone | Q28317165 |
| Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs | Q28329458 | ||
| Atrial flutter in patients treated for atrial fibrillation with propafenone | Q28336014 | ||
| Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol | Q28340406 | ||
| Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation | Q28340885 | ||
| Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy | Q33167798 | ||
| Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs | Q33174249 | ||
| Life-threatening flecainide toxicity. A pharmacodynamic approach | Q34166190 | ||
| New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. The CAST and CAPS Investigators. | Q34338535 | ||
| Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. | Q34387461 | ||
| Proarrhythmia in patients treated for atrial fibrillation or flutter | Q36212688 | ||
| Antiarrhythmic agents and the danger of proarrhythmic events | Q38656270 | ||
| The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis | Q39523454 | ||
| Proarrhythmic events | Q39626235 | ||
| Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs | Q39892125 | ||
| Antiarrhythmic drug action. Blockade of the inward sodium current | Q40077780 | ||
| Risks and benefits of antiarrhythmic therapy | Q40691893 | ||
| Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia | Q40692991 | ||
| Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital | Q41572384 | ||
| Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy | Q42214611 | ||
| Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care | Q42221096 | ||
| Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest | Q42253562 | ||
| Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation | Q44976893 | ||
| Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. | Q45992123 | ||
| An account of the foxglove, and some of its medical uses:with practical remarks on dropsy, and other diseases | Q51437318 | ||
| Sick sinus syndrome | Q66899887 | ||
| Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia--a status report, 1987 | Q69008773 | ||
| Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade | Q69343574 | ||
| Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation | Q69639939 | ||
| Effect of hypertonic sodium bicarbonate on encainide overdose | Q70136479 | ||
| Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect | Q70339529 | ||
| Risk factors for the development of proarrhythmic events | Q70339535 | ||
| Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment | Q70412437 | ||
| Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients | Q70970719 | ||
| Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients | Q71072125 | ||
| Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram | Q71267319 | ||
| Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs | Q72664804 | ||
| Early Afterdepolarizations Produced by d,1‐Sotalol and Clofilium | Q73482144 | ||
| Paroxysmal ventricular tachycardia and fibrillation due to quinidine | Q76086191 | ||
| Successful treatment of quinidine and procaine amide intoxication; report of three cases | Q78395448 | ||
| P433 | issue | 8A | |
| P304 | page(s) | 50N-58N | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Proarrhythmia | |
| P478 | volume | 82 |
| Q90627894 | A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm |
| Q46373751 | Acceleration of ventricular rate following atrial antitachycardia pacing: what is the mechanism? |
| Q43140041 | Adenosine-induced tachycardia acceleration: an unusual proarrhythmia |
| Q24187110 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation |
| Q24197643 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation |
| Q24243067 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation |
| Q73236827 | Atrial Fibrillation |
| Q35877363 | Cost effectiveness of therapies for atrial fibrillation. A review |
| Q77157597 | Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up |
| Q37527066 | Limitations to antiarrhythmic drug use in patients with atrial fibrillation |
| Q46631229 | Long-term efficacy of hybrid pharmacologic and ablation therapy in patients with pilsicainide-induced atrial flutter. |
| Q35680156 | Management of atrial fibrillation in the post-cardiac surgery setting |
| Q35547234 | Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. |
| Q35962527 | Pharmacological cardioversion of atrial fibrillation: current management and treatment options |
| Q42285626 | Proarrhythmic Effects Of Antiarrhythmic Drugs: Case Study Of Flecainide Induced Ventricular Arrhythmias During Treatment Of Atrial Fibrillation. |
| Q37408756 | Prognosis and natural history of drug-related bradycardia |
| Q34027332 | Redefining the role of antiarrhythmic drugs in the management of ventricular arrhythmias |
| Q37995638 | Safety of flecainide |
| Q35110915 | Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers |
| Q35170048 | Therapeutic drug monitoring of antiarrhythmic drugs |
| Q34505579 | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
| Q73738247 | [Consensus document for the management of patients with atrial fibrillation in hospital emergency departments] |
Search more.